Italy boost lifts European markets off lows
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St climbs after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
AstraZeneca (AZN) Reports T010 Phase III ETHOS Trial Met its Primary Endpoint in Chronic Obstructive Pulmonary Disease
August 28, 2019 7:01 AM EDTAstraZeneca (NYSE: AZN) today announced positive results from the Phase III ETHOS trial for triple-combination therapy PT010 in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
At the standard budesonide dose, PT010 (budesonide/glycopyrronium/formoterol fumarate 320/14.4/9.6mcg) demonstrated a statistically-significant reduction in the rate of moderate or severe exacerbations compared with dual-combination therapies glycopyrronium/formoterol fumarate 14.4/9.6mcg and PT009 (budesonide/formoterol fumarate 320/9.6mcg).
At half of the budesonide dose, PT010 (budesonide/glycopyrronium/formoterol fumarate 160/14.4/9.6mcg) also demonstrated a statistically-significant reduction in the rate of moderate or severe exacerbations compared with... More
